Kraj: Wielka Brytania
Język: angielski
Źródło: VMD (Veterinary Medicines Directorate)
Lincomycin
Vetpharma Animal Health, S.L
QJ01FF02
Lincomycin
Powder for use in drinking water
POM-V - Prescription Only Medicine – Veterinarian
Chickens, Pigs
Antimicrobial
Authorized
2017-07-19
Revised: August 2022 AN: 02021/2021 & 02022/2021 Page 1 of 7 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT OCNIL 400 mg/g powder for use in drinking water 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each gram contains: ACTIVE SUBSTANCE: Lincomycin ...................................................................................400 mg _(equivalent to 450 mg of lincomycin hydrochloride)_ EXCIPIENTS: For the full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Powder for use in drinking water. White powder, inodorous and without lumps. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Pigs and Chickens. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES PIGS Treatment and metaphylaxis of enzootic pneumonia caused by _Mycoplasma _ _hyopneumoniae_. The presence of the disease in the group must be established before the product is used. CHICKENS: Treatment and metaphylaxis of necrotic enteritis caused by _Clostridium _ _perfringens._ The presence of the disease in the group must be established before the product is used. 4.3 CONTRAINDICATIONS Do not use in cases of hypersensitivity to the active substance or to any of the excipients. Revised: August 2022 AN: 02021/2021 & 02022/2021 Page 2 of 7 Do not administer, and do not allow access to water containing lincomycin, to rabbits, hamsters, guinea pigs, chinchillas, horses or ruminants as this could result in severe gastrointestinal disturbances. Do not use in cases of resistance to lincosamides. Do not use in cases of hepatic dysfunction. 4.4 SPECIAL WARNINGS FOR TARGET SPECIES Medicated drinking water uptake can be affected by the severity of the disease. In case of insufficient uptake of water, pigs should be treated parenterally. The susceptibility of _Mycoplasma hyopneumoniae_ to antimicrobial agents is difficult to test _in vitro_ owing to technical constraints. In addition, there is a lack of clinical breakpoints for both _ M. hyopneumoniae_ and _ C. perfringens_. Where possible, therapy should be based on local (regional Przeczytaj cały dokument